Author

M. S. Tallman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

C. Famulare· 3 shared A. D. Goldberg· 2 shared E. M. Stein· 2 shared M. Patel· 2 shared M. Roshal· 2 shared R. L. Levine· 2 shared S. F. Cai· 2 shared A. Chan· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Famulare

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia

W. Xiao, A. Chan, M. R. Waarts, T. Mishra, Y. Liu, S. F. Cai, J. Yao, Q. Gao, R. L. Bowman, R. Koche, I. S. Csete, J. Baik, S. Yanis, C. Famulare, M. Patel, , R. Levine

This study identifies pDC-AML as a distinct AML subset with high RUNX1 mutations and pDC transcriptional features, suggesting CD123 targeting as a therapeutic strategy.

Blood · Mar 11, 2021Peer-reviewedPathology

Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition

S. F. Cai, S. H. Chu, A. D. Goldberg, S. Parvin, R. P. Koche, J. L. Glass, E. M. Stein, M. S. Tallman, F. Sen, C. Famulare, M. Cusan, C.-H. Huang, C.-W. Chen, L. Zou, K. B. Cordner, , S. A. Armstrong

This study shows that leukemia cell of origin affects apoptotic priming and sensitivity to LSD1 inhibitors, with Evi1 modulating p53 stability and activity.

bioRxiv · May 11, 2020Cancer Biology

Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

J. J. Harding, M. A. Lowery, A. H. Shih, J. M. Schvartzman, S. Hou, C. Famulare, M. Patel, M. Roshal, R. K. G. Do, A. Zehir, D. You, S. D. Selcuklu, A. Viale, M. S. Tallman, D. M. Hyman, , A. M. Intlekofer

The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.

bioRxiv · Aug 1, 2018Cancer Biology